Journal Article

American Joint Committee on Cancer Tumor–Node–Metastasis Stage After Neoadjuvant Chemotherapy and Breast Cancer Outcome

Lisa A. Carey, Richard Metzger, E. Claire Dees, Frances Collichio, Carolyn I. Sartor, David W. Ollila, Nancy Klauber-DeMore, Jan Halle, Lynda Sawyer, Dominic T. Moore and Mark L. Graham

in JNCI: Journal of the National Cancer Institute

Volume 97, issue 15, pages 1137-1142
Published in print August 2005 | ISSN: 0027-8874
Published online August 2005 | e-ISSN: 1460-2105 | DOI: http://dx.doi.org/10.1093/jnci/dji206
American Joint Committee on Cancer Tumor–Node–Metastasis Stage After Neoadjuvant Chemotherapy and Breast Cancer Outcome

Show Summary Details

Preview

Background: Response to neoadjuvant chemotherapy is used as an intermediate endpoint for breast cancer relapse and survival. Most breast cancer response classification systems use pathologic complete response, either alone or in conjunction with clinical assessments, to categorize response. We examined the ability of the revised 2003 American Joint Committee on Cancer (AJCC) tumor–node–metastasis (TNM) staging system, which considers both the number of involved axillary lymph nodes and the extent of tumor in the breast to predict patient survival after neoadjuvant chemotherapy for breast cancer. Methods: We assessed the pathologic stage of residual tumor in 132 patients with nonmetastatic breast cancer after they had undergone neoadjuvant chemotherapy and examined the association between AJCC TNM stage and subsequent distant disease–free survival and overall survival. All statistical tests were two-sided. Results: At a median follow-up of 5 years, pathologic stage in the surgical specimens after neoadjuvant chemotherapy using the revised AJCC system was strongly associated with both distant disease–free survival and overall survival. A higher pathologic stage of residual tumor after neoadjuvant chemotherapy was associated with a statistically significant lower rate of distant disease–free survival (stage 0: 95%, stage I: 84%, stage II: 72%, and stage III: 47%; Ptrend<.001). The 5-year distant disease–free survival for patients with residual stage IIIC tumors was only 18% (95% CI = 0% to 36%). Conclusion: Classification of residual tumor in the breast and axillary surgical specimens after neoadjuvant chemotherapy using the revised AJCC TNM system is useful for predicting distant relapse and survival.

Journal Article.  4212 words.  Illustrated.

Subjects: Medical Oncology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.